Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages e35-e42 , July 2007

Quotidian Hemodialysis and Inflammation Associated With Chronic Kidney Disease

  • Leslie Hamlett
    • ,
  • Lukas Haragsim

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lukas Haragsim, MD, Nephrology Section, University of Oklahoma Health Sciences Center, 920 S. L. Young Blvd, WP2250, Oklahoma City, OK 73104.

References 

  1. US Renal Data System: USRDS 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  2. Foley R, Parfrey P, Sarnak M. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S16–S23
  3. Kim BS, Jeon DS, Shin MJ, et al. Persistant elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189–195
  4. Goodman WG. Vascular calcification in end-stage renal disease. J Nephrol. 2002;15(suppl 6):S82–S85
  5. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and rennin-angiotensin system. Atheroscler Thromb Vasc Biol. 2002;22:1257–1266
  6. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
  7. Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998;54:1337–1343
  8. Stenvinkel P, Lindholm B, Heimburger O. Novel approaches on an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dialysis. 2004;17:505–515
  9. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  10. Stedman TL. In: Stedman’s Medical Dictionary. (ed 26). Baltimore, MD: Williams and Wilkins; 1995;p. 869
  11. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218
  12. Urieli-Shoval S, Linke R, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64–69
  13. Bathon J, Graves J, Jens P, et al. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis. 1987;10:34–40
  14. Ortega O, Rodriguez I, Gallar P, et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant. 2002;17:1105–1109
  15. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
  16. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  17. Memoli B, Libetta C, Rampino T, et al. Hemodialysis-related induction of interleukin-6 production by peripheral blood mononuclear cells. Kindey Int. 1992;42:320–326
  18. Liu Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006;17:863–870
  19. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92
  20. Pecoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor in mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17:1684–1688
  21. Conti G, Amore A, Chiesa M, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol. 2005;18:282–288
  22. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 2005;67:1216–1233
  23. Pereira BJ, Shapiro L, King AJ, et al. Plasma levels of IL-1 beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney Int. 1994;45:890–896
  24. Seyrek N, Karayaylali I, Balal M, et al. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients?. Scand J Urol Nephrol. 2005;39:405–409
  25. Kalousova M, Zima T, Tesar V. Carbonyl stress and chronic renal failure. Casopis Lekaru Ceskych. 2002;141:143–145
  26. Miyata T, Oda O, Inagi R, et al. Beta 2-microglobulin modified with advanced glycation end product is a major component of hemodialysis-associated amyloidosis. J Clin Invest. 1993;92:1243–1252
  27. Morena M, Dilbosc S, Dupuy A, et al. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis associated inflammation. Hemodialysis Int. 2005;9:37–46
  28. Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–2438
  29. Babior BM. NADPH oxidase: An update. Blood. 1999;93:1464–1476
  30. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol. 2003;14:353–359
  31. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int. 1998;53:416–422
  32. Sharma R, Bolger AP, Li W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol. 2003;92:188–193
  33. Kjellstrand CM, Evans RL, Peterson RJ, et al. The “unphysiology” of dialysis: A major cause of dialysis side effects?. Kidney Int. 1975;7:S30–S34
  34. Lindsay RM, Leitch R, Heidenheim A, et al. The London Daily/Nocturnal Hemodialysis Study—Study design,morbidity, and mortality results. Am J Kidney Dis. 2003;42(suppl 1):5–12
  35. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting “daily” hemodialysis. Kidney Int. 1999;55:2467–2476
  36. Nesrallah G, Suri R, Moist L, et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003;42:13–17
  37. Fagugli RM, Reboldi G, Quintaliani G. Short daily dialysis: Blood pressure control and left ventricular mass reduction in hypertensive patients. Am J Kidney Dis. 2001;38:371–376
  38. Mahmud A, Freely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118–1122
  39. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective controlled study. J Am Soc Nephrol. 2005;16:2778–2788
  40. Chan CT, Floras JS, Miller JA, et al. Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002;17:1518–1521
  41. Torun D, Sezer S, Baltali M, et al. Association of cardiac valve calcification and inflammation in patients on hemodialysis. Ren Fail. 2005;27:221–226
  42. Chan CT, Li SH, Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol. 2005;289:F679–F684
  43. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109:2058–2067
  44. Jofre R, Rodriguez-Benitez P, Lopez-Gomez J, et al. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 2006;17:274–280
  45. Nadra I, Mason J, Phillippides P, et al. Proinflammatory activation of macrophages by basic calcium phosphate crystal via protein kinase C and MAP kinase pathways (A vicious cycle of inflammation and arterial calcification). Circ Res. 2005;96:1248–1256
  46. Chan CT, Mardirossian S, Faratro R, et al. Improvement of lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis. 2003;41:225–229
  47. Kaysen G, Elserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial. 2003;16:438–446
  48. Bugeja AL, Chan CT. Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. Trans Am Soc Artif Intern Organs. 2004;50:328–331
  49. Trey JE, Kushner I. The acute phase response and the hemotopoietic system (The role of cytokines). Crit Rev Oncol Hematol. 1995;21:1–18
  50. Yuen D, Richardson R, Fenton S, et al. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Trans Am Soc Artif Intern Organs. 2005;51:236–241
  51. Schwartz DI, Pierratos A, Richardson RM, et al. Impact of nocturnal hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005;63:202–208
  52. Beddhu S, Kaysen GA, Yan G, et al. HEMO Study Group Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis. 2002;40:721–727
  53. Beddhu S, Pappas LM, Ramkumar N, et al. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol. 2004;15:733–742
  54. Eustace JA, Astor B, Muntner PM, et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int. 2004;65:1031–1040
  55. Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614–1622
  56. Fagugli RM, Vanholder R, De Smet R, et al. Advanced glycation end products: Specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs. 2001;24:256–262
  57. Ikizler TA, Flakoll PJ, Parker RA, et al. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994;46:830–837
  58. Pierratos A. Nocturnal home hemodialysis: An update on a 5-year experience. Nephrol Dial Transplant. 1999;14:2835–2840
  59. Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int. 2001;60:1555–1560
  60. Wiggins KJ, Somerville CA, Knight R, et al. Intradialytic protein concentrations differ between nightly nocturnal and conventional hemodialysis. Nephrology. 2005;10:325–329
  61. Spanner E, Suri R, Heidenheim AP, et al. The impact of quotidian hemodialysis on nutrition. Am J Kidney Dis. 2003;42(suppl 1):30–35
  62. Lindsay RM, Nesrallah G, Suri R, et al. Is more frequent hemodialysis beneficial and what is the evidence?. Curr Opin Nephrol Hypertens. 2004;13:631–635
  63. Nokher W, Scherberich J. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int. 1995;48:1469–1476
  64. Griveas I, Visvardis G, Sakellariou G, et al. Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers. Ren Fail. 2006;28:493–499
  65. Korevaar JC, van Manen JG, Dekker FW, et al. NECOSAD Study Group Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916–2922
  66. Azevedo SM, Carmichael WW, Jochimsen EM, et al. Human intoxication by microcystins during renal dialysis treatment in Caruaru-Brazil. Toxicology. 2002;181:441–446
  67. Hoenich NA, Levin R. The implication of water quality in hemodialysis. Semin Dial. 2003;16:492–497
  68. Schiffl H, Lang SM, Stratakis D, et al. Effect of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001;16:1863–1869
  69. Ward RA. Ultrapure dialysate. Semin Dial. 2004;17:489–497
  70. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by continuous microinflammation. Nephron. 2002;91:452–455
  71. Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in hemodialysis evaluated by darbepoetin requirements—A randomized study. Nephrol Dial Transplant. 2006;21:2851–2858
  72. Amore A, Cirina P, Bonaudo R, et al. Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. J Nephrol. 2006;19:57–64
  73. Kaysen GA. The microinflammatory state in uremia and causes and potential consequences. J Am Soc Nephrol. 2001;12:1549–1557
  74. Piccoli GB, Bermond F, Mezza E, et al. Vascular access survival and morbidity on daily dialysis: A comparative analysis of home and limited care hemodialysis. Nephrol Dial Transplant. 2004;19:2084–2094

PII: S1548-5595(07)00050-X

doi: 10.1053/j.ackd.2007.03.006

Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages e35-e42 , July 2007

Article Tools